US2011166189A1PendingUtilityA1

Methods of using sustained release aminopyridine compositions

57
Assignee: BLIGHT ANDREW RPriority: Apr 9, 2004Filed: Jun 25, 2010Published: Jul 7, 2011
Est. expiryApr 9, 2024(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/28A61P 25/00A61P 17/02A61P 21/00A61P 19/08A61K 31/435A61K 31/4409A61K 31/44A61K 9/20
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Claims

exact text as granted — not AI-modified
1 . A method of establishing steady state plasma pharmacokinetics of 4-aminopyridine, said method comprising administering sustained release 4-aminopyridine, as set forth herein. 
     
     
         2 . The method of  claim 1  further comprising a step of maintaining the steady state plasma pharmacokinetics of 4-aminopyridine.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.